Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06074497




Registration number
NCT06074497
Ethics application status
Date submitted
3/10/2023
Date registered
10/10/2023

Titles & IDs
Public title
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.
Scientific title
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation Trial of KGX101 Monotherapy and in Combination With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.
Secondary ID [1] 0 0
KGX101ST101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced or Metastatic Solid Tumors 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - KGX101- Cohort -1
Treatment: Drugs - KGX101- Cohort 1
Treatment: Drugs - KGX101- Cohort 2
Treatment: Drugs - KGX101- Cohort 3
Treatment: Drugs - KGX101- Cohort 4
Treatment: Drugs - KGX101- Cohort 5
Treatment: Drugs - KGX101 and Envafolimab

Experimental: KGX101- Cohort -1 - Dosage level: Dose level 1 Dose form: White-like lyophilized powder Route of administration: Intravenous

Experimental: KGX101- Cohort 1 - Dosage level: Dose level 2. Dose form: White-like lyophilized powder Route of administration: Intravenous

Experimental: KGX101- Cohort 2 - Dosage level: Dose level 3 Dose form: White-like lyophilized powder Route of administration: Intravenous

Experimental: KGX101- Cohort 3 - Dosage level: Dose level 4 Dose form: White-like lyophilized powder Route of administration: Intravenous

Experimental: KGX101- Cohort 4 - Dosage level: Dose level 5 Dose form: White-like lyophilized powder Route of administration: Intravenous

Experimental: KGX101- Cohort 5 - Dosage level: Dose level 6 Dose form: White-like lyophilized powder Route of administration: Intravenous

Active comparator: KGX101 and Envafolimab - Part B combination therapy KGX101 with Envafolibmab. Dose form: Injection Route to administration: Injection


Treatment: Drugs: KGX101- Cohort -1
Single dose of 0.1, 0.3, 1µg/kg of KGX101 every 3 weeks

Treatment: Drugs: KGX101- Cohort 1
Single dose of 0.3, 1.0, 3.0µg/kg of KGX101 every 3 weeks

Treatment: Drugs: KGX101- Cohort 2
Single dose of 1, 1 and 3µg/kg of KGX101 every 3 weeks

Treatment: Drugs: KGX101- Cohort 3
Single dose of 1,3 and 6µg/kg of KGX101 every 3 weeks

Treatment: Drugs: KGX101- Cohort 4
Single dose of 1,3,12µg/kg of KGX101 every 3 weeks

Treatment: Drugs: KGX101- Cohort 5
Single dose of 2, 5 and 15 µg/kg of KGX101 every 3 weeks

Treatment: Drugs: KGX101 and Envafolimab
Part B combination therapy KGX101 with Envafolibmab. 400mg to be injected subcutaneously with each target dose of KGX101 every 3 weeks. The dose escalation committee (DEC) may decide to increase the dosage to 600mg. based on PK, PD and safety data.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with Treatment emergent Adverse events (TEAEs)
Timepoint [1] 0 0
From baseline to 30 days after the last dose administration.
Primary outcome [2] 0 0
Number of participants with Dose Limiting Toxicities (DLTs) at week 4
Timepoint [2] 0 0
From Day 1 after the first dose of KGX101 full treatment to D21 post dose.
Primary outcome [3] 0 0
Number of participants with changes to clinical laboratory abnormalities
Timepoint [3] 0 0
Screening to 90 days post last dose administration
Primary outcome [4] 0 0
To estimate the Maximum tolerated dose of KGX101 monotherapy and combination therapy with Envafolimab.
Timepoint [4] 0 0
From Day 1 after the first dose of KGX101 full treatment to D21 post dose.
Secondary outcome [1] 0 0
PK Parameters: Maximum Concentration (Cmax)
Timepoint [1] 0 0
Part A- From pre-dose of the first dose of KGX101 full treatment to Day 90 after the first and 4th dose of full treatment; Part B- Predose and 72hrs (only 1st treatment)
Secondary outcome [2] 0 0
PK Parameters: Time of maximum observed concentration (Tmax)
Timepoint [2] 0 0
Part A- From pre-dose of the first dose of KGX101 full treatment to Day 90 after the first and 4th dose of full treatment; Part B- Predose and 72hrs (only 1st treatment)
Secondary outcome [3] 0 0
PK Parameters: Area under the curve (AUC)
Timepoint [3] 0 0
Part A- From pre-dose of the first dose of KGX101 full treatment to Day 90 after the first and 4th dose of full treatment; Part B- Predose and 72hrs (only 1st treatment)
Secondary outcome [4] 0 0
PK Parameters: Half- life (T1 /2)
Timepoint [4] 0 0
Part A- From pre-dose of the first dose of KGX101 full treatment to Day 90 after the first and 4th dose of full treatment; Part B- Predose and 72hrs (only 1st treatment)
Secondary outcome [5] 0 0
PK Parameters- Trough concentration (Ctrough)
Timepoint [5] 0 0
Part A- From pre-dose of the first dose of KGX101 full treatment to Day 90 after the first and 4th dose of full treatment; Part B- Predose and 72hrs (only 1st treatment)
Secondary outcome [6] 0 0
PK Parameters- Systemic clearance (CL)
Timepoint [6] 0 0
Part A- From pre-dose of the first dose of KGX101 full treatment to Day 90 after the first and 4th dose of full treatment; Part B- Predose and 72hrs (only 1st treatment)
Secondary outcome [7] 0 0
Immunogenicity- Anti-drug antibody (ADA)
Timepoint [7] 0 0
Part A- From pre-dose of the first dose of KGX101 full treatment to Day 90 hours after the first and 4th dose of full treatment; Part B- Predose and 72hrs (only 1st treatment)
Secondary outcome [8] 0 0
PK Parameters- Volume of distribution (Vd)
Timepoint [8] 0 0
Part A- From pre-dose of the first dose of KGX101 full treatment to Day 90 hours after the first and 4th dose of full treatment; Part B- Predose and 72hrs (only 1st treatment)
Secondary outcome [9] 0 0
Number of participants with changes in the Investigator-assessed confirmed Best Overall Response (BOR)
Timepoint [9] 0 0
From Day 1 after the first dose of KGX101 full treatment to D21 post dose.
Secondary outcome [10] 0 0
Number of participants with changes in the Overall Response (ORR)
Timepoint [10] 0 0
From Day 1 after the first dose of KGX101 till survival follow-up every 90 days post last treatment.
Secondary outcome [11] 0 0
Progression free survival (PFS) per RECIST 1.1
Timepoint [11] 0 0
From Day 1 after the first dose of KGX101 till survival follow-up every 90 days post last treatment.
Secondary outcome [12] 0 0
Overall survival
Timepoint [12] 0 0
From Day 1 after the first dose of KGX101 till survival follow-up every 90 days post last treatment.
Secondary outcome [13] 0 0
Change in serum concentration of KGX101 and total IL-12
Timepoint [13] 0 0
From Day 1 after the first dose of KGX101 till survival follow-up every 90 days post last treatment.

Eligibility
Key inclusion criteria
1. Part A: Any histologically or cytologically confirmed solid tumor malignancy that is locally advanced or metastatic and has failed standard therapy, or for which no further standard therapy exists.

Part B- In addition to above for Part B, participants should be tumor PD-L1 expression negative or with PD-L1 expression too low to fit for the immune checkpoint inhibitor treatment or have had disease progression after immune checkpoint inhibitor treatment.
2. Age at least 18 years.
3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1.
4. Has at least 1 measurable lesion per RECIST 1.1 (lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions).
5. Has adequate organ and bone marrow function as per the study (blood transfusion or use of use hematopoietic stimulating factor for correction within 14 days are not permitted):

1. Hematologic: White blood cell (WBC) count = 3 x 109/L; an absolute neutrophil count = 1.5 x 109/L; a hemoglobin level > 90 g/L; and a platelet count = 100 x 109/L;
2. Adequate hepatic function as defined by:

* Total bilirubin = 1.5 times the ULN if no liver metastases or = 2.5 times the ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases;
* Aspartate transaminase (AST), alanine transaminase (ALT) and Alkaline phosphatase (ALP) levels = 2.5 x the ULN or = 5 x the ULN for patients with liver metastases;
* Coagulation international normalized ratio (INR) and activated partial thromboplastin time (aPTT) = 1.5 x the ULN;
3. Adequate renal function as defined by a serum creatinine = 1.5 times the ULN concurrent with creatinine clearance = 50 mL/min (calculated by the Cockcroft-- Gault equation);
4. Biochemistry: albumin = 3.0g/dL
6. Willingness of men and women of reproductive potential to observe highly effective birth control for the duration of treatment and for 5 months following the last dose of study drug.
7. Paired pre-treatment archival tumor tissue within two years or fresh tumor biopsy and on-treatment fresh tumor biopsy will be optional. For participants of cutaneous malignant melanoma, paired pre-treatment archival tumor tissue and on-treatment fresh tumor biopsy should be mandatory
8. Life expectancy of approximately 3 months or longer in the opinion of the Investigator.
9. Provision of signed and dated written informed consent prior to any study-specific procedures, sampling, and analyses.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Active known second malignancy with the exception of any of the following: adequately treated basal cell carcinoma, squamous cell skin cancer, or in situ cervical cancer, breast cancer, papillary thyroid carcinoma; adequately treated stage I cancer from which the patient is currently in remission and has been in remission for = 2 years; low risk prostate cancer with Gleason score < 7 and prostate-specific antigen <10ng/mL; any other cancer from which the patient has been disease-free survival for = 5 years.
2. Patients with primary CNS malignancies.
3. A history of allogeneic tissue/solid organ transplant.
4. Any evidence of severe or uncontrolled systemic diseases, including:

1. Active, uncontrolled systemic bacterial, viral, or fungal infection;
2. uncontrolled hypertension (Systolic blood pressure more than equal to 160mHG or diastolic blod pressure more than equal to 100mm HG or poor compliance with anti-hypertensive agents;
3. or active bleeding diatheses;
4. Clinically significant arrhythmia, unstable angina pectoris, congestive heart failure (class III or IV of New York Heart Association [NYHA]) or acute myocardial infarction within 6 months;
5. Uncontrolled diabetes or poor compliance with hypoglycemic agents;
6. The presence of chronically unhealed wound or ulcers;
7. Other chronic diseases, which, in the opinion of the Investigator, could compromise safety of the patient or the integrity of study.
5. Active autoimmune disease requiring systemic treatment in the past 2 years.
6. Diagnosis of immunodeficiency, is on immunosuppressive therapy, or is receiving chronic systemic or enteric steroid therapy.
7. A history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.
8. HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
9. Active infection as determined by hepatitis B surface antigen and hepatitis B core antigen antibody, or hepatitis B virus DNA by quantitative polymerase chain reaction (qPCR) testing.
10. Active infection as determined by hepatitis C virus (HCV) antibody or HCV RNA by qPCR testing.
11. Major surgery (excluding placement of vascular access) within 4 weeks prior to the first dose of study drug.
12. Treatment with any of the following:

1. Prior treatment with IL-12 therapy (any form, e.g. recombinant human, prodrug, intratumoral, etc.);
2. Presence of CNS metastases that are symptomatic and/or require local CNS directed therapy (such as XRT or surgery) or increasing doses of corticosteroids within 2 weeks prior to the first dose of study drug. Except patients with treated brain metastases should be neurologically stable and receiving less than equal to 10mg per day of prednisone or equivalent prior to study entry;
3. Investigational agent or anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, anticancer Chinese medicine, or anticancer herbal remedy) within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug;
4. Radiotherapy within 2 weeks of the start of study treatment. A 1-week washout is permitted for palliative radiation (less than equal to two weeks of radiotherapy) to non-CNS disease;
5. Received a live or live-attenuated vaccine within 30 days of the first dose of study drug; Note: Administration of killed vaccines or other formats are allowed;
6. Diagnosis of immunodeficiency, on immunosuppressive therapy, or receiving chronic systemic or enteric steroid therapy (dose > 10 mg/day of prednisone or equivalent);
7. Prior receipt of an allogeneic stem cell transplant or allogeneic CAR-T cell therapy;
13. Any unresolved toxicities from prior therapy greater than NCI CTCAE version 5.0 Grade 1 at the time of starting study drug with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy, and medical history conditions requiring maintenance therapy such as, but not limited to, hypothyroidism and adrenal insufficiency, where the principal investigator (PI) has the discretion to determine the appropriate severity classification at study screening, contingent upon the patient's screening labs not showing clinically significant abnormalities and meeting the eligibility requirements as per sponsor and site PI approval.
14. Electrocardiogram QT interval corrected for heart rate (QTc) > 470 msec, measured by Fridericia's formula [QTcF=QT/(RR0.33)]; or any of the following cardiac events within 6 months before screening: Myocardial infarction; unstable angina; unstable symptomatic ischemic heart disease; New York Heart Association class III or IV heart failure; Thromboembolic events (eg, pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, or severe congenital heart disease).
15. Any illness, medical condition, organ system dysfunction, or social situation (including mental illness or substance abuse), that may interfere with a patient's ability to sign the ICF, adversely affect the patient's ability to cooperate and participate in the study, or compromise interpretation of study results.
16. Pregnant (confirmed by serum beta human chorionic gonadotropin [ HCG]) or lactating.
17. History of hypersensitivity to any of the study drug components; or history experienced grade = 3 irAEs and leads to permanent discontinuation in prior immunotherapy.
18. Part B: participants who are not tolerant to immune checkpoint inhibitor therapy.
19. Participant is known or suspected of not being able to comply with the study protocol (e.g. because of alcoholism, drug dependency, or psychological disorder) or the participant has any condition for which, in the opinion of the Investigator, participation in the study would not be in the best interest of the participant (e.g. compromise their well-being) or that could prevent, limit, or confound the protocol-specified assessments. Or any other disease or clinically medical status that the investigator considers the patient is unstable or may affect their safety or study compliance.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/12/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/05/2026
Actual
Sample size
Target
54
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Pindara Private Hospital - Benowa
Recruitment hospital [2] 0 0
Sunshine Coast University Private Hospital - Birtinya
Recruitment hospital [3] 0 0
Peninsula & South Eastern Haematology and Oncology Group - Frankston
Recruitment postcode(s) [1] 0 0
4217 - Benowa
Recruitment postcode(s) [2] 0 0
4575 - Birtinya
Recruitment postcode(s) [3] 0 0
3199 - Frankston

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Kangabio AUSTRALIA LTD PTY
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Weidong Jiang, Dr
Address 0 0
Chief Executive Officer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Yi Zhao
Address 0 0
Country 0 0
Phone 0 0
+86 18019087115
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06074497